Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia.
about
Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies.The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development.NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia.Recent advances in anti-angiogenic therapy of cancer
P2860
Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia.
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Antiangiogenic activity of tha ...... sk acute myelogenous leukemia.
@ast
Antiangiogenic activity of tha ...... sk acute myelogenous leukemia.
@en
type
label
Antiangiogenic activity of tha ...... sk acute myelogenous leukemia.
@ast
Antiangiogenic activity of tha ...... sk acute myelogenous leukemia.
@en
prefLabel
Antiangiogenic activity of tha ...... sk acute myelogenous leukemia.
@ast
Antiangiogenic activity of tha ...... sk acute myelogenous leukemia.
@en
P2093
P2860
P1433
P1476
Antiangiogenic activity of tha ...... sk acute myelogenous leukemia.
@en
P2093
Brenda Cooper
Donna Kane
Howard Meyerson
Karen Stear
Mary Laughlin
Paul Hartman
Rania Reyes
Richard Creger
William Tse
P2860
P304
P356
10.1080/10428190701573208
P577
2007-10-01T00:00:00Z